NCT05218850RecruitingPhase 2
The Use of Butyrate Therapy in Pediatric Ulcerative Colitis
Butyrate Therapy in Hispanic Children With Ulcerative Colitis
Source: ClinicalTrials.gov · Last updated 4 Jun 2026
Brief summary (registry, in English)
Butyrate is an important metabolite produced by the gut microbiome and has been shown as a helpful therapy in ulcerative colitis. This is a feasibility study to determine the efficacy of butryate enemas in pediatric ulcerative colitis.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- First submitted
- 20 Jan 2022
- Start date
- 29 Jun 2022
- Primary completion date
- 30 Jun 2027
- Lead sponsor
- Children's Hospital Los Angeles
- Diseases
- Ulcerative colitis
- NCT number
- NCT05218850
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 10
- From 29 Jun 2022 to the primary completion date, 30 Jun 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- UC therapy within 4 weeks of study medication initiation
Other
- infectious colitis, -pregnancy
Who the study is looking for
- 7-21 years, mild to moderate ulcerative colitis
Age in the registry: 7 years to 21 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Children's Hospital Los Angeles Coordinator of this site? Confirm its status | Los Angeles | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.